You are here: Home: Audio Program Guide: BCU Think Tank 2 | 2008 Audio: BCU Think Tank 2 | 2008
 

 
  Go to Adjuvant Therapy
Go to Management of Metastatic Disease


 

To listen to individual tracks, click the track you wish to listen to.
To download tracks, right-click on the one you wish to download.


Section 1:

Adjuvant Therapy
   Click here to download the entire section  
Track 1 ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or combined with zoledronic acid
Track 2 Ovarian suppression as adjuvant therapy for premenopausal patients
Track 3 Potential mechanism of anticancer action of bisphosphonates
Track 4 Adjuvant bisphosphonates in clinical practice
Track 5 Delayed adjuvant endocrine therapy for patients with ER/PR-positive breast cancer
Track 6 Estrogen receptor-positive breast cancer and the risk of late recurrences

Track 7 Chronicity of recurrence risk in patients with ER/PR-positive breast cancer and optimal duration of adjuvant endocrine therapy
Track 8 Arthralgias secondary to aromatase inhibitors (AIs)
Track 9 Pathophysiology of AI-induced arthralgias
Track 10 Differential efficacy of anastrozole, letrozole and exemestane
Track 11 NCCTG-N9831: Cardiotoxicity data with adjuvant trastuzumab
Track 12 Assessing cardiac function in patients prior to and during treatment with trastuzumab
Track 13 Single-agent trastuzumab in the metastatic and adjuvant settings
Track 14 Accuracy of cardiac monitoring
Track 15 Phase II feasibility trial of dose-dense AC followed by paclitaxel concurrent with trastuzumab
Track 16 Concurrent versus sequential trastuzumab and chemotherapy
Track 17 Time course of recurrence in HER2-positive breast cancer
Track 18 Optimal duration of adjuvant trastuzumab

Track 19 Combining adjuvant trastuzumab with anthracycline-based therapy in clinical practice
Track 20 Anthracyclines as part of adjuvant therapy for patients with HER2-positive breast cancer
Track 21 Efficacy of trastuzumab in patients with HER2-low tumors
Track 22 Accuracy of HER2 testing
Track 23 Anti-HER2 therapy for patients with HER2-negative disease
Track 24 Adaptive overexpression of HER2 in patients with ER/PR-positive breast cancer treated with hormonal therapy
Track 25 Controversial impact of EGFR inhibition in HER2-positive breast cancer
Track 26 Improving methodology and accuracy of ER and HER2 testing
Track 27 US Oncology trial of docetaxel/cyclophosphamide (TC) versus TAC in patients with HER2-negative breast cancer
Track 28 Phase III trial of adjuvant TC versus TAC versus TC/bevacizumab in HER2-positive, early-stage breast cancer
Track 29 Hypertension associated with bevacizumab
Track 30 Correlation between toxicity and efficacy in targeted therapies

Track 31 Selection of adjuvant therapy for patients with triple-negative breast cancer
Track 32 Tolerability of AC versus TC in the adjuvant setting

Track 33 Consideration of alopecia in the selection of adjuvant therapy

Section 2:

Treatment of Metastatic Breast Cancer
   Click here to download the entire section  
Track 1 Clinical trials of the epothilone B analog ixabepilone in metastatic disease
Track 2 Hematologic toxicity of ixabepilone
Track 3 Phase III trial of capecitabine and ixabepilone: Toxicity data
Track 4 Ixabepilone combined with capecitabine or as monotherapy for advanced breast cancer
Track 5 Sequential versus combination chemotherapy in taxane- and anthracycline-resistant disease
Track 6 Response rates to chemotherapy in the later-line setting

Track 7 Selection and sequence of chemotherapy for advanced breast cancer based on quality of life
Track 8 CALGB-40502: A Phase III trial of paclitaxel versus nanoparticle albumin-bound (nab) paclitaxel versus ixabepilone combined with bevacizumab in Stage IIIB/IV breast cancer
Track 9 AVADO: Phase III trial results of docetaxel with or without bevacizumab as front-line therapy for locally recurrent or metastatic breast cancer
Track 10 Mechanism of action and dosing of bevacizumab in various tumor types
Track 11 Rationale and risks of combining anti-angiogenic agents in clinical practice
Track 12 Defining tumor dormancy and the potential impact of anti-angiogenesis
Track 13 Multiple theories on the mechanism of action of bevacizumab
Track 14 Second-line therapy with or without bevacizumab for disease progression after front-line
bevacizumab
Track 15 Utility of maintenance bevacizumab in clinical practice
Track 16 Theoretical efficacy of bevacizumab in early-stage versus advanced breast cancer
Track 17 Efficacy of docetaxel, paclitaxel and nab paclitaxel
Track 18 Phase II trial of front-line nab paclitaxel and bevacizumab for advanced breast cancer
Track 19 Phase II study of dual VEGF and HER2 receptor blockade with neoadjuvant bevacizumab/
trastuzumab combined with nab paclitaxel/carboplatin for HER2-positive, locally advanced
breast cancer
Track 20 Avoidance of premedication with nab paclitaxel
Track 21 Phase III trial results of capecitabine with or without trastuzumab in patients experiencing disease
progression during trastuzumab treatment

Track 22 Clinical trial data with lapatinib alone or combined with trastuzumab in heavily pretreated patients
experiencing disease progression on trastuzumab therapy
Track 23 Tolerability of trastuzumab versus lapatinib
Track 24 Phase II trial of trastuzumab and pertuzumab in HER2-positive, trastuzumab-resistant, metastatic
breast cancer
Track 25 Phase I trials of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate
Track 26 Future development of agents targeting HER2